Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates
Portfolio Pulse from Benzinga Newsdesk
Moderna expects its 2023 Covid-19 sales to be between $6B-$8B, depending on U.S. vaccination rates. The company is resizing its manufacturing footprint and supply base to accelerate gross margin expansion towards its longer-term target of 75-80%.
September 13, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's projected sales for 2023 are dependent on U.S. vaccination rates. The company's efforts to resize its manufacturing could lead to gross margin expansion, potentially boosting its financial performance.
Moderna's sales projections are directly tied to U.S. vaccination rates, which could fluctuate based on various factors. However, the company's efforts to optimize its manufacturing processes could lead to increased gross margins, which would positively impact its financial performance and potentially its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100